Invivyd Inc. has announced the initiation of the DECLARATION clinical trial, a Phase 3 randomized, triple-blind, placebo-controlled study evaluating VYD2311, an investigational monoclonal antibody designed for the prevention of COVID-19. The DECLARATION trial will assess the efficacy and safety of VYD2311 in preventing symptomatic COVID-19 in adults and adolescents, with participants receiving either a single intramuscular dose or monthly doses, compared to placebo. The primary endpoint is reduction in PCR-confirmed symptomatic COVID incidence versus placebo at three months. The company expects to enroll approximately 1,770 participants across all study arms. Top-line results from the trial are anticipated in mid-2026. No results have been presented yet.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Invivyd Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9616340) on December 23, 2025, and is solely responsible for the information contained therein.